Dr. Reddy's Laboratories Ltd.
Fundamentals
- Market cap
- ₹1.13 lakh cr
- P/E
- 26.86×
- ROE
- 16.86%
- Debt / equity
- 0.14
- Div yield
- 0.60%
- 52-week range
- 1148.40 — 1375.90
Company snapshot
Dr. Reddy's Laboratories Ltd.
Pharmaceuticals
₹1.13 L cr
P/E 26.83×
Latest quarter · Mar 2026
Sales₹7,546 cr
Net profit₹217 cr
Op. margin+5.1%
EPS₹2.65
Strength & growth
Debt / equity0.20×
Current ratio1.79×
Sales CAGR+8.0%
EPS CAGR+9.6%
The timeline — 3 notes on Dr. Reddy's Laboratories Ltd.
July 2026
- 09 Jul 26 · 5:23 PM IST Brief Brief · Mega cap
Dr. Reddy's halves semaglutide supply guidance after API impurity
An API impurity in validation batches forces Dr. Reddy's to cut FY27 pen target from 12M to 6-7M. Commercial supply to partner One Source now expected in October, retail from November.
- 09 Jul 26 · 9:18 AM IST Brief Brief · Mega cap
Dr. Reddy's delays generic semaglutide supply after API issue
Certain batches out of specification; commercial supplies on hold. Company says no patient safety or regulatory filing impact, schedules conference call.